Christoph Burkart, PhD

aTyr Pharma
San Diego, CA, United States

Associate Director / Translational Sciences

Presentation(s):

• 1322: Efzofitimod, a First-in Class NRP2-targeting Immunomodulator, Ameliorates Rheumatoid Arthritis and Associated Lung Fibrosis in Preclinical Models

  Monday, November 13, 2023
  9:00 AM – 11:00 AM PT

  Disclosure information not submitted.